CRSP
CRISPR TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull assumes successful pivotal readouts, timely approvals, and early commercial traction that expand revenue and justify premium multiples.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -6.2.
What can break
Competitive advances compressing addressable market
Momentum
43
Value
41
Sentiment
89
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $69.00 · Bull $120.00 · Bear $35.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-23 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $81.21
Why
Momentum43 · Δ7d +15.7
Value41 · Δ7d +0.1
Sentiment89 · Δ7d -6.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
43
34% active weight
Current posture
7d trendFlat
Δ7d
+15.7
Δ21d
+8.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
89
33% active weight
Current posture
7d trendSoftening
Δ7d
-6.2
Δ21d
+9.3
Why this grade
Composite grade B. Momentum 42.7 / Value 41.1 / Sentiment 88.7
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$5.23B
Beta
1.72
Shares Out
95.3M
P/E (TTM) · Derived
-8.5
P/S (TTM)
137.09
P/FCF (TTM) · Derived
-14.62
Rev YoY
+47.7%
EPS YoY
-15.6%
Gross Margin
-
Op Margin
-1498.3%
Net Debt
-$1.9B
Current Ratio
16.22
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology